Companies Flatiron Health

Flatiron Health

New York

Total Offices: 2

2,500 Total Employees

Year Founded: 2012

View Website

We're Hiring!

HR & Recruiting 4 Marketing 2 Operations & Support 1 Sales 1

View all jobs

Flatiron Health Company Growth, Stability & Outlook in New York

Updated on September 09, 2026

What's the stability & growth outlook for Flatiron Health?

The New York office is characterized by participation in a company expanding internationally, investing in AI-driven products, and building partnerships that connect work to real-world clinical settings. Together, these dynamics suggest the New York location offers exposure to global projects, emerging oncology technologies, and collaborative initiatives embedded in care delivery.

Key Insight for Candidates

New York is an actively invested hub, with current openings spanning engineering, research, product, legal, and people, amid Flatiron’s broader expansion in networks, partnerships, and conference presence. For candidates, this means joining a cross‑functional center of activity with frequent exposure to high‑impact, externally visible work.

Evidence in Action

Cross-Functional New York Hiring — Flatiron’s careers page currently lists openings across New York, Durham, London, and Tokyo, spanning engineering, research, product, legal, and people functions. This signals ongoing investment and provides New York employees visible pathways for role mobility and growth.
Global Network Expansion — Flatiron Health UK’s first Scottish partnership with NHS Greater Glasgow and Clyde described a nearly 70% expansion of its global network. New York teams gain broader collaboration and evidence‑generation opportunities across expanding international sites.

Positive Themes About Flatiron Health

Market Expansion: Teams in New York are part of an organization expanding its global oncology network, including new partnerships in the UK and growth across Europe and Japan. This broader footprint ties New York work to multinational evidence generation and collaboration.
Innovation-Driven Growth: Work in New York aligns with active product and AI capability development, such as the launch of an AI platform for oncology insights and new AI-powered datasets and validation frameworks in 2026. These initiatives signal an emphasis on building new tools that advance real-world oncology evidence.
Strategic Partnerships: New York teams operate within a company deepening collaborations at the point of care and in research, including integrations with major diagnostics firms and partnerships with health systems and consortia. These relationships embed projects in clinical workflows and extend the impact of local efforts.